Technology area: Biotechnology & Pharmaceuticals
12 pending office actions • 8 art units • 11 examiners • 0 of 12 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Taiho Pharmaceutical Co., Ltd. has 12 pending office actions in Biotechnology & Pharmaceuticals. The portfolio spans 11 distinct examiners and 8 distinct art units, reflecting broad distribution across the examining organization. Prosecution management must therefore accommodate variation in examiner practice and technical focus.
FETTEROLF, BRANDON J is the busiest examiner, with 2 pending matters. That examiner merits focused review for consistency, while the remaining matters require separate planning. Counsel should coordinate claim strategy and evidence centrally but adapt responses to each art-unit and examiner setting.
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (8%) |
| §102 only | 1 (8%) |
| §112 only | 3 (25%) |
| Double-patenting + other | 2 (17%) |
| Multi-statute (no §101) | 5 (42%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FETTEROLF, BRANDON J | 2 | 51.6% | +18.5% |
| PURDY, KYLE A | 1 | 41.0% | +35.7% |
| BRAUN, MADELINE E | 1 | 68.4% | +25.3% |
| KOSAR, ANDREW D | 1 | 41.9% | +31.9% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.4% | +24.3% |
| YOUNGBLOOD, WILLIAM JUSTIN | 1 | 60.0% | +41.6% |
| RODRIGUEZ, RAYNA B | 1 | 33.6% | +19.2% |
| KONOPELSKI SNAVEL, SARA ELIZABETH | 1 | 35.0% | +35.4% |
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.7% |
| COPPINS, JANET L | 1 | 72.6% | +26.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17786504 | THERAPEUTIC AGENT CONTAINING FUSED PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | WILLIS, DOUGLAS M | 3d overdue |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18563058 | TREATMENT METHODS FOR SUBJECTS WITH CANCER HAVING AN ABERRATION IN EGFR AND/OR HER2 | FETTEROLF, BRANDON J | 9d |
| 16627146 | CHEMOTHERAPY FOR CANCER USING AZABICYCLO COMPOUND | MCKOY, QUINCY ANDRE | 22d |
| 18026515 | METHODS OF TREATING RIBONUCLEOTIDE REDUCTASE-RELATED DISEASES WITH A RIBONUCLEOTIDE REDUCTASE INHIBITOR | RODRIGUEZ, RAYNA B | 23d |
| 18704901 | PROCESS FOR PREPARING A BENZOATE SALT OF A 1-(3-AMINOPYRROLIDINE-1-CARBONYL)-3,4-DIPHENYLBENZENE COMPOUND | KOSAR, ANDREW D | — |
| 18549249 | TREATING CANCER IN PATIENT HAVING CO-OCCURRING GENETIC ALTERATION IN FGFR2 AND A CANCER DRIVER GENE | WHITE, DAWANNA SHAR-DAY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17788847 | AGENT FOR ADJUVANT THERAPY | KONOPELSKI SNAVEL, SARA ELIZABETH | 88d overdue |
| 17786504 | THERAPEUTIC AGENT CONTAINING FUSED PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | WILLIS, DOUGLAS M | 3d overdue |
| 18563058 | TREATMENT METHODS FOR SUBJECTS WITH CANCER HAVING AN ABERRATION IN EGFR AND/OR HER2 | FETTEROLF, BRANDON J | 9d |
| 18253521 | Crystalline Forms of 4-amino-N-[4-(methoxymethyl)phenyl]-7-(1-methylcyclopropyl)-6-(3-morpholinoprop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide, Methods of Preparation, and uses Thereof | FETTEROLF, BRANDON J | 15d |
| 18026515 | METHODS OF TREATING RIBONUCLEOTIDE REDUCTASE-RELATED DISEASES WITH A RIBONUCLEOTIDE REDUCTASE INHIBITOR | RODRIGUEZ, RAYNA B | 23d |
| 18873090 | PHARMACEUTICAL COMPOSITION CONTAINING PIMITESPIB | PURDY, KYLE A | — |
| 18713496 | SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS | BRAUN, MADELINE E | — |
| 18704901 | PROCESS FOR PREPARING A BENZOATE SALT OF A 1-(3-AMINOPYRROLIDINE-1-CARBONYL)-3,4-DIPHENYLBENZENE COMPOUND | KOSAR, ANDREW D | — |
| Art Unit | Apps |
|---|---|
| 1626 | 3 |
| 1624 | 2 |
| 1628 | 2 |
| 1611 | 1 |
| 1625 | 1 |
| 1627 | 1 |
| 1629 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18873090 | PHARMACEUTICAL COMPOSITION CONTAINING PIMITESPIB | PURDY, KYLE A | 1611 | §103 | Non-Final OA | — | Pending | Dec 09, 2024 |
| 18713496 | SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS | BRAUN, MADELINE E | 1624 | §102§103§112DP | Non-Final OA | — | Pending | May 24, 2024 |
| 18704901 | PROCESS FOR PREPARING A BENZOATE SALT OF A 1-(3-AMINOPYRROLIDINE-1-CARBONYL)-3,4-DIPHENYLBENZENE COMPOUND | KOSAR, ANDREW D | 1625 | §103§112 | Non-Final OA | — | Pending | Apr 25, 2024 |
| 18563058 | TREATMENT METHODS FOR SUBJECTS WITH CANCER HAVING AN ABERRATION IN EGFR AND/OR HER2 | FETTEROLF, BRANDON J | 1626 | §102§103Other | Non-Final OA | 9d | Pending | Nov 21, 2023 |
| 18549249 | TREATING CANCER IN PATIENT HAVING CO-OCCURRING GENETIC ALTERATION IN FGFR2 AND A CANCER DRIVER GENE | WHITE, DAWANNA SHAR-DAY | 1627 | §102§103Other | Final Rejection | — | Pending | Sep 06, 2023 |
| 18253521 | Crystalline Forms of 4-amino-N-[4-(methoxymethyl)phenyl]-7-(1-methylcyclopropyl)-6-(3-morpholinoprop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide, Methods of Preparation, and uses Thereof | FETTEROLF, BRANDON J | 1626 | §112 | Non-Final OA | 15d | Pending | May 18, 2023 |
| 18253229 | Methods of Using 4-Amino-N-[4-(Methoxymethyl)Phenyl]-7-(1-Methylcyclopropyl)-6-(3-Morpholinoprop-1-YN-1-YL)-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carboxamide for the Treatment of Tumors | YOUNGBLOOD, WILLIAM JUSTIN | 1629 | §102Other | Final Rejection | — | Pending | May 17, 2023 |
| 18026515 | METHODS OF TREATING RIBONUCLEOTIDE REDUCTASE-RELATED DISEASES WITH A RIBONUCLEOTIDE REDUCTASE INHIBITOR | RODRIGUEZ, RAYNA B | 1628 | §103§112Other | Final Rejection | 23d | Pending | Mar 15, 2023 |
| 17788847 | AGENT FOR ADJUVANT THERAPY | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §103DP | Non-Final OA | 88d overdue | Pending | Jun 24, 2022 |
| 17786504 | THERAPEUTIC AGENT CONTAINING FUSED PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | WILLIS, DOUGLAS M | 1624 | §112 | Non-Final OA | 3d overdue | Pending | Jun 16, 2022 |
| 17432158 | PHARMACEUTICAL COMPOSITION AND THERAPEUTIC METHOD FOR TREATING FGFR1 VARIANT-POSITIVE BRAIN TUMOR | COPPINS, JANET L | 1628 | §112 | Final Rejection | — | Pending | Aug 19, 2021 |
| 16627146 | CHEMOTHERAPY FOR CANCER USING AZABICYCLO COMPOUND | MCKOY, QUINCY ANDRE | 1626 | §103§112Other | Final Rejection | 22d | Pending | Dec 27, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTaiho Pharmaceutical Co., Ltd. has 12 pending office actions as of October 2026, spread across 8 art units and 11 examiners.
Brandon J Fetterolf has the most, with 2 of Taiho Pharmaceutical Co., Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
